share_log

Anixa Biosciences And 3 Other Stocks Under $5 Insiders Are Buying

Anixa Biosciences And 3 Other Stocks Under $5 Insiders Are Buying

anixa biosciences和其他3只股票的内部人士正在购买
Benzinga ·  07/29 07:13

The Dow Jones index closed higher by over 650 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道琼斯指数周五收盘上涨了650多点。当内部人士购买或出售股票时,这表明他们对公司前景的信心或担忧。对于对便士股感兴趣的投资者和交易者,他们可以将此视为其整体投资或交易决策的因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是几个近期关于低价股的值得关注的内部交易。了解更多,请查看Benzinga内幕交易平台。

ARCA biopharma

方舟生物医药

  • The Trade: ARCA biopharma, Inc. (NASDAQ:ABIO) 10% owner Janus Henderson Biotech Innovation Master Fund Ltd bought a total of 220,083 shares at an average price of $3.18. To acquire these shares, it cost around $699,165.
  • What's Happening: On April 25, ARCA biopharma posted a first-quarter loss of 14 cents per share.
  • What ARCA biopharma Does: ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases.
  • 交易:ARCA生物制药公司(纳斯达克:ABIO)的10%股东珍珠昆士兰生物医学创新主基金有限公司以平均价格3.18美元购买了220083股。为了获得这些股票,花费约为699165美元。
  • 动态:4月25日,方舟生物医药公布第一季度每股亏损14美分。
  • 方舟生物医药公司是一家临床阶段的生物医药公司,采用精准医学方法开发和商业化心血管疾病的靶向治疗方案。

Anixa Biosciences

Anixa生物科技

  • The Trade: Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Arnold M Baskies acquired a total of 5,000 shares at an average price of $3.09. To acquire these shares, it cost around $15,450.
  • What's Happening: On July 23, Anixa Biosciences announced that its collaborator, Moffit Cancer Center, has received FDA approval for an individual patient Investigational New Drug Application (IND) to allow a second dose of its CAR-T therapy for a patient that may be demonstrating clinical activity to the initial treatment.
  • What Anixa Biosciences Does: Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology.
  • 交易:Anixa生物科技公司(纳斯达克:ANIX)董事Arnold m Baskies以平均价格3.09美元购买了5000股。为了获得这些股票,花费约为15450美元。
  • 正在发生的事情:7月23日,Anixa生物科技宣布其合作伙伴莫法特癌症中心获得了FDA批准,针对可能对初始治疗展示临床活性的患者进行个体化的新药申请(IND),以允许进行第二次CAR-t疗法治疗。
  • Anixa生物科技公司是一家专注于癌症的生物技术公司,正在开发针对肿瘤学中关键未满足需求的疫苗和治疗方法。

Lifeloc Technologies

Lifeloc Technologies

  • The Trade: Lifeloc Technologies, Inc. (OTC:LCTC) CFO Vern D Kornelsen acquired a total of 45,620 shares at an average price of $3.80. The insider spent around $173,356 to buy those shares.
  • What's Happening: On July 26, Lifeloc Technologies named Adam Kashenberg to its Board of Directors.
  • What Lifeloc Technologies Does: Lifeloc Technologies Inc is a developer, manufacturer, and marketer of portable hand-held and fixed station breathalyzers and related accessories, supplies and education.
  • 交易:Lifeloc Technologies公司(场外交易:LCTC)首席财务官Vern D Kornelsen以平均价格3.80美元购买了45620股。内部人士花费约173356美元购买这些股票。
  • 正在发生的事情:7月26日,Lifeloc Technologies任命Adam Kashenberg为其董事会成员。
  • Lifeloc Technologies公司是便携式掌持式及固定位呼气式酒精测试仪及相关附件、用品和教育的开发、制造和销售商。

Cyanotech

赛安诺科技

  • The Trade: Cyanotech Corporation (OTC:CYAN) Director Michael A / Davis acquired a total of 10,000 shares at an average price of $0.62. The insider spent around $6,200 to buy those shares.
  • What's Happening: On June 26, Cyanotech reported net sales of $23,071,000 for fiscal 2024 compared to $23,178,000 in fiscal 2023.
  • What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.
  • 交易:Cyanotech公司(场外交易:CYAN)董事Michael A/Davis以平均价格0.62美元购买了10000股。内部人士花费约6200美元购买这些股票。
  • 近况:6月26日,Cyanotech报告称,2024财年净销售额为2,307.1万美元,而2023财年为2,317.8万美元。
  • 赛安诺科技公司从微藻中提炼可用于营养补充剂市场的天然产品。
  • Top 3 Risk Off Stocks That Are Set To Fly In July
  • 7月份即将飞涨的前3只风险股票
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发